Svoboda and colleagues reported therapeutic doses in the range of 3 × 106 to 30 × 106 CAR T cells in patients with R/R NHL (NCT04684563) using IL18 secreting autologous 19.BBζ CAR T cells (huCART19-IL18; ref. 130). The gene discussed is IL18; the disease is non-Hodgkin lymphoma.